Microstructure of Vertebrae,Ribs, and Gastralia of Triassic Sauropterygians—New Insights into the Microanatomical Processes Involved in Aquatic Adaptations of Marine Reptiles

Isolated ribs and vertebrae of Middle Triassic sauropterygians are studied. The vertebrae have a well-defined large cavity in their centra, which is a unique feature and is without any modern analogue. The articular facets of vertebrae are made of endochondral bone including calcified as well as uncalcified cartilage. Vertebrae are pachyosteosclerotic in the pachypleurosaurs Neusticosaurus and Serpianosaurus from the Alpine Triassic, and osteosclerotic in the placodont, in the medium-sized Nothosaurus marchicus, and in the pachypleurosaur Anarosaurus. In large Nothosaurus specimens, the vertebrae are cavernous. The ribs of all sampled specimens are osteosclerotic, which resembles the microanatomy of long bones in all studied taxa. The proximal to medial part of ribs mainly consists of a compact periosteal cortex surrounding an inner endosteal territory. Toward the distal end of the ribs, the periosteal thickness decreases whereas the endosteal territory increases. Despite a shift from periosteal versus endosteal tissues, global rib compactness remains relatively constant. Osteosclerosis in ribs and vertebrae is reached by the same processes as in the long bones: by a relative increase in cortex thickness that is coupled by a reduction of the medullary cavity, by the persistence of calcified cartilage, and by an inhibition of remodeling although some resorption may occur but without complete redeposition of bone. Processes differ from those observed in Permian marine reptiles and some mosasaurines, where either extensive remodeling or inhibition of bone resorption leads to osteosclerosis. Besides differences regarding the microanatomy, all studied bones of a taxon are consistent in their bone tissue type. Anat Rec, 302:1770–1791, 2019. © 2019 American Association for Anatomy     

Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma

Data indicate reversal of immune dysfunction with active treatment; however, the precise contribution of specific immune effector and immune suppressor components to achieve a minimal residual disease (MRD) state and immunomodulatory drug–mediated immunomodulatory effects in multiple myeloma (MM) patients remains poorly understood. In this prospective proof-of-principle study we sought to determine the dynamic alterations in natural killer (NK), NK-T, and T cells, including maturation and activating/inhibitory repertoire associated with MRD^pos versus MRD^neg status after autologous stem cell transplantation (ASCT) and during lenalidomide-based maintenance therapy. Of the 46MM patients enrolled, 36 had bone marrow MRD assessment 60+ days post-ASCT, 30 had longitudinal blood immunotyping during maintenance (pretherapy and after cycles 1, 3, and 6), and 20 had both MRD assessment and longitudinal immunotyping. Multicolor flow cytometry was used for MRD and immunotyping. Although the absolute number of NK cells was significantly lower in patients with MRD^pos response, phenotypically NK cells in these patients displayed higher expression of activating receptors KIRDS4 and decreased expression of inhibitory molecules NKG2A compared with the MRD^neg group. Furthermore, we observed significantly lower frequencies of T cells displaying KIR3DL1 in MRD^pos versus MRD^neg patients. Longitudinal immunotyping during lenalidomide maintenance showed loss of mature NK effector function, augmentation of NK-T effector function, and acquisition of PD1 independent anergic state. Our findings also suggest skewing of T cells toward an exhausted state during the maintenance phase in MRD^pos patients. Put together, these observations provide a distinctive signature for MRD^neg and MRD^pos groups. These data support exploration of immune profiling in prospective clinical trials according to MRD-defined responses to identify patients that may benefit from maintenance intensification/modification or maintenance withdrawal.     

Sodium-23 solid-state nuclear magnetic resonance of commercial sodium naproxen and its solvates

We report on the investigation of sodium coordination environments with solid-state 23Na nuclear magnetic resonance (NMR) spectroscopy of various hydrates and solvates of sodium naproxen (SN), a commercially available anti-inflammatory drug sold over the counter as Aleve?, among other names. The 23Na quadrupolar coupling constant is found to change significantly depending on the hydration state, and subtle changes in oxygen coordination environment about the sodium cations were apparent in the NMR spectra. High-resolution double-rotation NMR experiments are also performed on powdered samples to obtain solution-like 23Na NMR spectra. Our attempts at crystallizing various solvates of SN have led to the characterization of the first crystal structure for the heminonahydrated form. The composition of commercial SN is also investigated and it is shown that Aleve? is composed of approximately 80% monohydrate solvate. Density-functional theory calculations, using the gauge-including projector-augmented-wave formalism, allow for the assignment of 23Na NMR peaks to specific sodium sites in the reported X-ray crystal structure.     

Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect?

Purpose

Fluindione is an oral vitamin K antagonist (indanedione derivative) exclusively marketed in France and Luxembourg, known to have immuno-allergic adverse effects such as hepatitis, fever or interstitial nephritis. A few cases of drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with fluindione. The aim of the present study was to investigate fluindione-induced DRESS cases reported in France and to describe their characteristics.

Methods

We searched for potential cases of DRESS with fluindione reported in the French pharmacovigilance database since 2000.

Results

Thirty-six cases of DRESS were included and concerned 17 women and 19 men. The mean age was 65?years (median: 68?years, range: 28?C95?years). Kidneys and liver were the most frequent organs involved. Thirty-five cases were serious. In 5 cases, the effect was life-threatening. Most of the patients recovered. Fluindione was the only medicine suspected in 26 cases. Skin patch tests, performed in 10 cases, were positive with fluindione in 9 cases.

Conclusions

Fluindione is not known to be a frequent cause of DRESS. However, the number of reports found is probably underestimated. The seriousness of DRESS, as all immuno-allergic adverse effects, contraindicates fluindione reintroduction. Coumarinic derivatives are the alternatives in patients who need oral anticoagulant treatment.     

Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report

PurposeTo examine whether three cycles of a low-intensity chemotherapy consisting of cyclophosphamide [500 mg/m² – day 1], vinblastine [6 mg/m² – days 1 and 8] and prednisolone [40 mg/m² – days 1–7] (CVP) is safe and therapeutically effective in children and adolescents with early stage nodular lymphocyte predominant Hodgkin lymphoma [nLPHL].Patients and methodsFifty-five children and adolescents with early stage nLPHL [median age 13 years, range 4–17 years] diagnosed between June 2005 and October 2010 in the UK and France are the subjects of this report. Staging investigations included conventional cross sectional as well as 18 fluro-deoxyglucose [FDG] PET imaging. Histology was confirmed as nLPHL by an expert pathology panel.ResultsOf the 45 patients, who received CVP as first line treatment, 36 [80%, 95% Confidence Interval [CI]: (68; 92)] either achieved a complete remission [CR] or CR unconfirmed [CRu], the remaining nine patients achieved a partial response. All nine subsequently achieved CR with salvage chemotherapy [n = 7] or radiotherapy [n = 2]. Ten patients received CVP at relapse after primary treatment that consisted of surgery alone and all achieved CR. To date, only three patients have relapsed after CVP chemotherapy and all had received CVP as first line treatment at initial diagnosis. The 40-month freedom from treatment failure and overall survival for the entire cohort were 75.4% (SE ± 6%) and 100%, respectively. No significant early toxicity was observed.ConclusionsOur results show that CVP is an effective chemotherapy regimen in children and adolescents with early stage nLPHL that is well tolerated with minimal acute toxicity.